CVRx Yönetim

Yönetim kriter kontrolleri 3/4

CVRx CEO'su Kevin Hykes, Feb2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.12% doğrudan sahiptir ve bu hisselerin değeri $ 401.99K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.6 yıl ve 3.3 yıldır.

Anahtar bilgiler

Kevin Hykes

İcra Kurulu Başkanı

US$137.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report

Nov 01

Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)

Oct 10

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Jul 31

Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge

Jun 18

Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

Feb 18

CVRx: The Path To 7x Investment Returns

Jan 07

CEO

Kevin Hykes (58 yo)

less than a year

Görev süresi

US$137,004

Tazminat

Mr. Kevin Hykes serves as Director of CVRx, Inc. since December 21, 2022 and serves as President and Chief Executive Officer since February 12, 2024. He served as President, Director & Chief Executive Offi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin Hykes	President	less than a year	US$137.00k	0.12% $ 402.0k
Jared Oasheim	Chief Financial Officer	4.1yrs	US$1.32m	0.064% $ 207.0k
Paul Verrastro	Chief Marketing & Strategy Officer	3.8yrs	US$1.08m	0.0033% $ 10.8k
Paul Pignato	Vice President of Operations	2.8yrs	Veri yok	Veri yok
Jonelle Burnham	VP & General Counsel	1.7yrs	Veri yok	Veri yok
Tonya Austin	Chief Human Resources Officer	less than a year	Veri yok	Veri yok
Jennifer Englund	Senior Vice President of Global Clinical Affairs	less than a year	Veri yok	Veri yok
Philip Adamson	Chief Medical Officer	less than a year	Veri yok	Veri yok
Bonnie Handke	Senior Vice President of Patient Access	less than a year	Veri yok	Veri yok
Robert John	Chief Revenue Officer	less than a year	Veri yok	Veri yok

0.6yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: CVRX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin Hykes	President	1.9yrs	US$137.00k	0.12% $ 402.0k
Mitchell Hill	Director	less than a year	Veri yok	Veri yok
Joseph Slattery	Independent Director	16.1yrs	US$167.45k	0.13% $ 410.6k
Kirk Nielsen	Independent Director	4.3yrs	US$165.30k	0% $ 0
Mudit Jain	Independent Director	4.3yrs	US$158.98k	0.014% $ 45.6k
Kevin Ballinger	Director	less than a year	Veri yok	Veri yok
Martha Shadan	Independent Director	3.3yrs	US$147.45k	0% $ 0

3.3yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CVRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

CVRx Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CVRx, Inc. Announces Board Changes

President recently bought US$251k worth of stock

CVRx, Inc. Announces Appointment of Robert Allen John as Chief Revenue Officer, Effective June 27, 2024

CVRx, Inc. Announces Executive Appointments

CVRx, Inc., Annual General Meeting, Jun 04, 2024

Chief Marketing & Strategy Officer notifies of intention to sell stock

Recent updates

Price target increased by 9.8% to US$15.00

Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report

CVRx, Inc. Revises Earnings Guidance for the Full Year of 2024

CVRx, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)

CVRx, Inc. Announces Board Changes

President recently bought US$251k worth of stock

CVRx, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Second quarter 2024 earnings: EPS misses analyst expectations

CVRx, Inc. to Report Q2, 2024 Results on Jul 29, 2024

CVRx, Inc.(NasdaqGS:CVRX) dropped from Russell Small Cap Comp Value Index

CVRx, Inc. Announces Appointment of Robert Allen John as Chief Revenue Officer, Effective June 27, 2024

Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge

New major risk - Share price stability

CVRx, Inc. Announces Executive Appointments

Consensus EPS estimates fall by 28%

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%

CVRx, Inc. Provides Earnings Guidance for Second Quarter and Full Year of 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CVRx, Inc., Annual General Meeting, Jun 04, 2024

CVRx, Inc. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Shareholder dilution

Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%

Chief Marketing & Strategy Officer notifies of intention to sell stock

CVRx, Inc. Announces Chief Executive Officer Changes, Effective February 12, 2024

CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12, 2024

CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12

Full year 2023 earnings: EPS exceeds analyst expectations

CVRx, Inc. to Report Q4, 2023 Results on Jan 25, 2024

CVRx, Inc. Announces Nadim Yared Retires as Chief Executive Officer

CVRx, Inc. Announces Nadim Yare Retires as President

CVRx, Inc. Receives FDA Approval for Expanded Labing of Barostim

Price target increased by 16% to US$23.60

Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%

New minor risk - Share price stability

CVRx, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Price target decreased by 9.3% to US$19.40

CVRx, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. Revises Financial Guidance for the Full Year 2023

CVRx, Inc. to Report Q2, 2023 Results on Jul 25, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. to Report Q4, 2022 Results on Jan 26, 2023

CVRx, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022 and Provides Revenue Guidance for the First Quarter and Full Year of 2023

CVRx, Inc. Appoints Kevin Hykes to Board of Directors

Price target increased to US$17.25

Chief Marketing & Strategy Officer notifies of intention to sell stock

Price target increased to US$14.75

CVRx, Inc. Launches New Barostim NEO2(TM) Implantable Pulse Generator

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. announced that it expects to receive $65 million in funding from Innovatus Capital Partners, LLC

CVRx, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth

CVRx Pursues Revenue Growth But Operating Losses Worsen

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CVRx, Inc. Revises Earnings Guidance for the Full Year of 2022

CVRx, Inc. to Report Q2, 2022 Results on Jul 28, 2022

CVRx, Inc. Launches A New Barostim Programmer

CVRx, Inc.(NasdaqGS:CVRX) dropped from Russell 2500 Value Index

CVRx: Barostim Story Looks Well Priced In, Overvalued At Just 5x Sales

CVRx, Inc. Receives U.S. Food and Drug Administration Approval for Magnetic Resonance Conditional Labeling for Its Barostim System

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

CVRx, Inc., Annual General Meeting, Jun 07, 2022

CVRx, Inc. to Report Q1, 2022 Results on Apr 25, 2022

We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth